10.1371/journal.pone.0044935 86 GrnewaldA.KumarK
Effects of Once-Weekly Semaglutide on Appetite, Energy Intake, Control of Eating, Food Preference and Body Weight in Subjects With Obesity
doi: 10.1093/ije/dyr233 21 MacKinnonDPFairchildAJFritzMS

(T)aking GLP-1RAs may be associated with an increased risk of kidney cancer, highlighting the need for longer-term follow-up to clarify the underlying mechanisms and clinical implications of these findings. GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity, JAMA Oncology Despite the risks being slight, researchers noted that there were more than 137 million individuals currently eligible to take GLP-1 medications in the U.S., and that even modest changes in cancer risk could have substantial public health implications. Ozempic, Mounjaro Gastroparesis Lawsuits Individuals nationwide are pursuing more than 2,400 product liability lawsuits brought throughout the federal court system over the past two years, each indicating that Novo Nordisk and Eli Lilly, the manufacturers of Ozempic and Mounjaro respectively, failed to provide adequate warning that the diabetes and weight loss drugs could cause severe gastrointestinal problems

Its important to monitor for signs of an allergic response, such as hives or difficulty breathing
Wegovy FAQs How much does Wegovy cost